Section Arrow
Quote
EQ.NASDAQ
- Equillium
(Financial Status)
Quotes are at least 15-min delayed:2025/06/02 13:56 EDT
Last
 0.38
-0.01 (-2.56%)
Day High 
0.393 
Prev. Close
0.39 
1-M High
0.4499 
Volume 
85.91K 
Bid
0.3751
Ask
0.38
Day Low
0.35 
Open
0.39 
1-M Low
0.3442 
Market Cap 
13.93M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.38 
20-SMA 0.39 
50-SMA 0.46 
52-W High 1.51 
52-W Low 0.3442 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.39/-0.78
Enterprise Value
14.12M
Balance Sheet
Book Value Per Share
0.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
41.10M
Operating Revenue Per Share
0.95
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.172799+0.052799+44.00%-- 
PSTVPlus Therapeutics0.5368+0.2499+87.10%-- 
PCSAProcessa Pharmaceuticals0.3062+0.0137+4.68%-- 
BPMCBlueprint Medicines Corp127.605+26.255+25.91%-- 
IRDOpus Genetics Inc1.1691+0.1746+17.56%-- 
Quotes are at least 15-min delayed：2025/06/02 13:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.